# US 2017/0253631 A1 · Hexapeptide for neuroprotection against a beta toxicity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253631 A1
- Document ID: US20170253631A1
- Status: Published application
- Kind: A1
- Application number: 15/062,773
- Filed: 2016-03-07
- Published: 2017-09-07
- Earliest claimed: 2016-03-07
- Assignees: Council of Scientific and Industrial Research
- Applicants: Council of Scientific and Industrial Research
- Inventors: Surajit Ghosh; Atanu Biswas; Batakrishna Jana; Saswat Mohapatra; Subhas Chandra Biswas; Suraiya Saleem; Prasenjit Mondal; Anindyasundar Adak; Subhajit Ghosh; Abhijit Saha; Debmalya Bhunia
- Web page: https://patentgrep.com/patent/US20170253631A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with β-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with Aβ peptide in-vitro and shows excellent neuroprotection against Aβ infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.

## Claims

### Claim 1

(canceled)

### Claim 2

A nanovesicle having size in the range of 50-600 nm comprising monomeric units of a peptide consisting of the amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 3

A method for preventing, for delaying onset or for treatment of Alzheimer's disease in a subject comprising administering a single or multi-dose effective amount of a peptide consisting of the amino acid sequence as set forth in SEQ ID NO: 1; or a nanovesicle having size in the range of 50-600 nm comprising monomeric units of a peptide consisting of the amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 4 (depends on 3)

The method as claimed in claim 3, further comprising concurrent administration of at least one more neuroprotective therapeutic agent to said subject.

### Claim 5 (depends on 3)

The method as claimed in claim 3, wherein said administration is intravenous.

### Claim 6

A peptide consisting of the amino acid sequence as set forth in SEQ ID NO: 1 further modified for imaging.

### Claim 7 (depends on 2)

The nanovesicle as claimed in claim 2, further modified for imaging.
